StockData
Vistagen Therapeutics, Inc. logo

Vistagen Therapeutics, Inc. (VTGN) stock

VTGNNasdaqPharmaceutical PreparationsFiscal year ends March 31
Financials through Q1 FY2027, quarter ended Jun 30, 2026Last filing: 10-Q on Nov 13, 2026Score 9/3078% below fair value
$0.20+0.01 (+6.12%)

Close on Nov 18, 2026Market cap $8.85MP/E –Yield –

Vistagen Therapeutics revenue

Revenue is the money a company takes in from selling its products and services, before any costs are deducted.

Vistagen Therapeutics's revenue for the twelve months ending Jun 30, 2026 was $2.50M. For fiscal 2026 it was $1.27M, up 161.1% from the year before. Over ten years it grew 20.3% a year on average. The highest annual figure on record is $2.07M in fiscal 2011.

Annual revenue

PeriodPeriod endValueChange
FY2026Mar 31, 2026$1.27M+161.1%
FY2025Mar 31, 2025$486.00K-54.3%
FY2024Mar 31, 2024$1.06M–
FY2023Mar 31, 2023-$227.00K-120.5%
FY2022Mar 31, 2022$1.11M+1.8%
FY2021Mar 31, 2021$1.09M–
FY2020Mar 31, 2020$0–
FY2018Mar 31, 2018$0-100.0%
FY2017Mar 31, 2017$1.25M–
FY2016Mar 31, 2016$0-100.0%
FY2013Mar 31, 2013$200.40K-85.1%
FY2012Mar 31, 2012$1.34M-35.2%
FY2011Mar 31, 2011$2.07M–

Quarterly revenue

Change is against the same quarter a year earlier.

Periods
PeriodPeriod endValueChange
Q1 FY2027CQ2 2026Jun 30, 2026$1.48M+504.9%
Q4 FY2026CQ1 2026Mar 31, 2026$465.00K+98.7%
Q3 FY2026CQ4 2025Dec 31, 2025$303.00K+65.6%
Q2 FY2026CQ3 2025Sep 30, 2025$258.00K+207.1%
Q1 FY2026CQ2 2025Jun 30, 2025$244.00K+23.9%
Q3 FY2025CQ4 2024Dec 31, 2024$234.00K-43.1%
Q2 FY2025CQ3 2024Sep 30, 2024$183.00K-34.2%
Q1 FY2025CQ2 2024Jun 30, 2024$84.00K-52.5%
Q4 FY2024CQ1 2024Mar 31, 2024$197.00K+11.9%
Q3 FY2024CQ4 2023Dec 31, 2023$411.00K+128.3%
Q2 FY2024CQ3 2023Sep 30, 2023$278.00K–
Q1 FY2024CQ2 2023Jun 30, 2023$177.00K-42.9%
Q4 FY2023CQ1 2023Mar 31, 2023$176.00K+351.3%
Q3 FY2023CQ4 2022Dec 31, 2022$180.00K-49.7%
Q2 FY2023CQ3 2022Sep 30, 2022-$893.00K-349.4%
Q1 FY2023CQ2 2022Jun 30, 2022$310.10K-12.4%
Q4 FY2022CQ1 2022Mar 31, 2022$39.00K-91.2%
Q3 FY2022CQ4 2021Dec 31, 2021$358.00K+14.2%
Q2 FY2022CQ3 2021Sep 30, 2021$358.00K+7.2%
Q1 FY2022CQ2 2021Jun 30, 2021$354.00K–
Q4 FY2021CQ1 2021Mar 31, 2021$442.00K–
Q3 FY2021CQ4 2020Dec 31, 2020$313.60K–
Q2 FY2021CQ3 2020Sep 30, 2020$334.00K–
Q1 FY2021CQ2 2020Jun 30, 2020$0–
Q4 FY2020CQ1 2020Mar 31, 2020$0–
Q3 FY2020CQ4 2019Dec 31, 2019$0–
Q2 FY2020CQ3 2019Sep 30, 2019$0–
Q1 FY2020CQ2 2019Jun 30, 2019$0-100.0%
Q4 FY2018CQ1 2018Mar 31, 2018$0–
Q3 FY2018CQ4 2017Dec 31, 2017$0–
Q4 FY2017CQ1 2017Mar 31, 2017$0–
Q3 FY2017CQ4 2016Dec 31, 2016$1.25M–
Q2 FY2017CQ3 2016Sep 30, 2016$0–

More Vistagen Therapeutics figures

See a number that looks wrong?